{"preliminary_commentary":{"by_channel":{"x_thread":3,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["cabozantinib"]],"indication":"unresectable, locally advanced or metastatic medullary thyroid cancer","name":"EXAM","nct_id":"NCT00704730","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=exam-nct00704730. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"EXAM","arms":[{"description":null,"label":"1","type":"EXPERIMENTAL"},{"description":null,"label":"2","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2020-09","type":"ACTUAL"},"conditions":["Thyroid Cancer"],"enrollment":{"count":330,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"XL184","otherNames":[],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"DRUG"}],"last_update":"2021-04-20","lead_sponsor":"Exelixis","official_title":"An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2011-10","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS)","timeFrame":"Treatment period consisted of 4-week cycles with radiologic tumor assessment every 12 weeks from date of randomization until date of first documented PD or date of death from any cause, whichever came first, assessed up to 34 months."}],"references":[{"citation":"Schlumberger M, Elisei R, Muller S, Schoffski P, Brose M, Shah M, Licitra L, Krajewska J, Kreissl MC, Niederle B, Cohen EEW, Wirth L, Ali H, Clary DO, Yaron Y, Mangeshkar M, Ball D, Nelkin B, Sherman S. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Ann Oncol. 2017 Nov 1;28(11):2813-2819. doi: 10.1093/annonc/mdx479.","pmid":"29045520","type":"DERIVED"},{"citation":"Elisei R, Schlumberger MJ, Muller SP, Schoffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10;31(29):3639-46. doi: 10.1200/JCO.2012.48.4659. Epub 2013 Sep 3.","pmid":"24002501","type":"DERIVED"}],"start_date":{"date":"2008-06"},"study_type":"INTERVENTIONAL","title":"Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer","url":"https://clinicaltrials.gov/study/NCT00704730"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/exam-nct00704730"}